

Edmund K Waller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7571931/publications.pdf>

Version: 2024-02-01

238
papers

12,046
citations

38660

50
h-index

30848

102
g-index

242
all docs

242
docs citations

242
times ranked

14383
citing authors

#	ARTICLE	IF	CITATIONS
1	Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2019, 380, 45-56.	13.9	2,594
2	Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors. <i>New England Journal of Medicine</i> , 2012, 367, 1487-1496.	13.9	762
3	Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 4199-4206.	0.8	433
4	Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. <i>Blood</i> , 2017, 130, 2243-2250.	0.6	352
5	The Role of Sargramostim (rhGM-CSF) as Immunotherapy. <i>Oncologist</i> , 2007, 12, 22-26.	1.9	345
6	Human Cytomegalovirus (CMV)-Induced Memory-like NKG2C+ NK Cells Are Transplantable and Expand In Vivo in Response to Recipient CMV Antigen. <i>Journal of Immunology</i> , 2012, 189, 5082-5088.	0.4	331
7	Impact of immune modulation with anti-CD28 antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. <i>Blood</i> , 2011, 117, 6963-6970.	0.6	322
8	Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 1403-1415.	5.1	222
9	Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 3141-3149.	0.8	212
10	Lymphoid Reconstitution After Autologous PBSC Transplantation With FACS-Sorted CD34+ Hematopoietic Progenitors. <i>Blood</i> , 1998, 91, 2588-2600.	0.6	159
11	CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCR β repertoire. <i>Blood</i> , 2015, 125, 3835-3850.	0.6	147
12	Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	142
13	Cryopreserved Mesenchymal Stromal Cells Are Susceptible to T-Cell Mediated Apoptosis Which Is Partly Rescued by IFN γ Licensing. <i>Stem Cells</i> , 2016, 34, 2429-2442.	1.4	131
14	Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 89-97.	2.0	130
15	Larger numbers of CD4 ^{bright} dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. <i>Blood</i> , 2001, 97, 2948-2956.	0.6	127
16	Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. <i>Blood</i> , 2013, 121, 197-206.	0.6	123
17	Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 460-471.	2.0	121
18	Indoles derived from intestinal microbiota act via type I interferon signaling to limit graft-versus-host disease. <i>Blood</i> , 2018, 132, 2506-2519.	0.6	120

#	ARTICLE	IF	CITATIONS
19	Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. <i>Journal of Clinical Oncology</i> , 2021, 39, 1865-1877.	0.8	111
20	Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation. <i>JAMA Oncology</i> , 2016, 2, 1583.	3.4	110
21	Circulating CD34 ⁺ Progenitor Cells and Risk of Mortality in a Population With Coronary Artery Disease. <i>Circulation Research</i> , 2015, 116, 289-297.	2.0	102
22	In Vivo T Cell Costimulation Blockade with Abatacept for Acute Graft-versus-Host Disease Prevention: A First-in-Disease Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1638-1649.	2.0	96
23	Factors of the bone marrow microniche that support human plasma cell survival and immunoglobulin secretion. <i>Nature Communications</i> , 2018, 9, 3698.	5.8	95
24	Effectiveness and cost analysis of just-in-time salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. <i>Transfusion</i> , 2011, 51, 2175-2182.	0.8	93
25	YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype. <i>Journal of Thoracic Oncology</i> , 2021, 16, 464-476.	0.5	93
26	The Potential of CAR T Cell Therapy in Pancreatic Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 2166.	2.2	92
27	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019, 3, 1826-1836.	2.5	89
28	Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. <i>Blood Advances</i> , 2020, 4, 560-572.	2.5	88
29	HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis. <i>Blood</i> , 2021, 138, 273-282.	0.6	88
30	Treatment of Relapsed Acute Leukemia after Allogeneic Transplantation: A Single Center Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 116-123.	2.0	87
31	Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3K \hat{I} inhibitors and VIP antagonists. <i>Blood Advances</i> , 2018, 2, 210-223.	2.5	87
32	Metabolomics of ADSOL (AS-1) Red Blood Cell Storage. <i>Transfusion Medicine Reviews</i> , 2014, 28, 41-55.	0.9	83
33	Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation. <i>Blood</i> , 2002, 99, 1085-1088.	0.6	77
34	Autoimmune neutropenia in adults. <i>Autoimmunity Reviews</i> , 2009, 9, 62-66.	2.5	77
35	Improved Survival After Transplantation of More Donor Plasmacytoid Dendritic or Na \hat{V} e T Cells From Unrelated-Donor Marrow Grafts: Results From BMTCTN 0201. <i>Journal of Clinical Oncology</i> , 2014, 32, 2365-2372.	0.8	77
36	Influenza vaccine-induced human bone marrow plasma cells decline within a year after vaccination. <i>Science</i> , 2020, 370, 237-241.	6.0	77

#	ARTICLE	IF	CITATIONS
37	IFN- γ and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity. <i>Blood</i> , 2012, 119, 1075-1085.	0.6	73
38	Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1636-1645.	2.0	71
39	Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. <i>Blood Advances</i> , 2018, 2, 299-307.	2.5	69
40	Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention. <i>Science Translational Medicine</i> , 2015, 7, 315ra191.	5.8	64
41	Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2002-2007.	2.0	64
42	Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. <i>Immunotherapy</i> , 2009, 1, 599-621.	1.0	62
43	Building blocks for institutional preparation of CTL019 delivery. <i>Cytotherapy</i> , 2017, 19, 1015-1024.	0.3	61
44	Low Doses of Imatinib Induce Myelopoiesis and Enhance Host Anti-microbial Immunity. <i>PLoS Pathogens</i> , 2015, 11, e1004770.	2.1	60
45	Irradiated Donor Leukocytes Promote Engraftment of Allogeneic Bone Marrow in Major Histocompatibility Complex Mismatched Recipients Without Causing Graft-Versus-Host Disease. <i>Blood</i> , 1999, 94, 3222-3233.	0.6	59
46	Dichotomous Role of Interferon- γ in Allogeneic Bone Marrow Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1347-1353.	2.0	59
47	Microfluidic Sorting of Cells by Viability Based on Differences in Cell Stiffness. <i>Scientific Reports</i> , 2017, 7, 1997.	1.6	59
48	Telomere Shortening, Regenerative Capacity, and Cardiovascular Outcomes. <i>Circulation Research</i> , 2017, 120, 1130-1138.	2.0	59
49	Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion. <i>Blood Advances</i> , 2019, 3, 2230-2236.	2.5	59
50	Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study. <i>American Journal of Hematology</i> , 2019, 94, 446-454.	2.0	56
51	PI3K γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity. <i>Blood</i> , 2022, 139, 523-537.	0.6	56
52	The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. <i>British Journal of Haematology</i> , 2016, 173, 96-104.	1.2	53
53	Microfluidic cell sorting by stiffness to examine heterogenic responses of cancer cells to chemotherapy. <i>Cell Death and Disease</i> , 2018, 9, 239.	2.7	52
54	Silibinin inhibits accumulation of myeloid-derived suppressor cells and tumor growth of murine breast cancer. <i>Cancer Medicine</i> , 2014, 3, 215-224.	1.3	51

#	ARTICLE	IF	CITATIONS
55	Microfluidic generation of transient cell volume exchange for convectively driven intracellular delivery of large macromolecules. <i>Materials Today</i> , 2018, 21, 703-712.	8.3	51
56	Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 629-637.	2.5	48
57	CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56 + T cells. <i>Cancer Immunology, Immunotherapy</i> , 2001, 49, 629-640.	2.0	46
58	Systems analysis uncovers inflammatory Th/Tc17-driven modules during acute GVHD in monkey and human T cells. <i>Blood</i> , 2016, 128, 2568-2579.	0.6	46
59	High Incidence of Severe Acute Graft-Versus-Host Disease with Tacrolimus and Mycophenolate Mofetil in a Large Cohort of Related and Unrelated Allogeneic Transplantation Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 979-985.	2.0	45
60	Flagellin, a TLR5 Agonist, Reduces Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation Recipients While Enhancing Antiviral Immunity. <i>Journal of Immunology</i> , 2011, 187, 5130-5140.	0.4	44
61	Immune dysfunctionality of replicative senescent mesenchymal stromal cells is corrected by IFN γ priming. <i>Blood Advances</i> , 2017, 1, 628-643.	2.5	43
62	A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 848-857.	2.0	42
63	Circulating Progenitor Cells Identify Peripheral Arterial Disease in Patients With Coronary Artery Disease. <i>Circulation Research</i> , 2016, 119, 564-571.	2.0	42
64	<i>KIR B</i> donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation. <i>Blood Advances</i> , 2020, 4, 740-754.	2.5	42
65	Progenitor Cells and Clinical Outcomes in Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	40
66	The Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism. <i>Oncotarget</i> , 2016, 7, 2936-2950.	0.8	40
67	Poly (I: C) modulates the immunosuppressive activity of myeloid-derived suppressor cells in a murine model of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 21-30.	1.1	38
68	Myeloablative vs reduced intensity T-cellâ€“replete haploidentical transplantation for hematologic malignancy. <i>Blood Advances</i> , 2019, 3, 2836-2844.	2.5	38
69	Allotransplantation for Patients Age â‰¥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 960-968.	2.0	37
70	Successful treatment of severe immune hemolytic anemia after allogeneic stem cell transplantation with bortezomib: report of a case and review of literature. <i>Transfusion</i> , 2015, 55, 259-264.	0.8	37
71	Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 466-471.e1.	0.2	37
72	Kinetics of immune cell reconstitution predict survival in allogeneic bone marrow and G-CSFâ€“mobilized stem cell transplantation. <i>Blood Advances</i> , 2019, 3, 2250-2263.	2.5	37

#	ARTICLE	IF	CITATIONS
73	Phosphoinositide 3-Kinase Signaling Can Modulate MHC Class I and II Expression. <i>Molecular Cancer Research</i> , 2019, 17, 2395-2409.	1.5	36
74	Progenitor Cells and Clinical Outcomes in Patients With Acute Coronary Syndromes. <i>Circulation Research</i> , 2018, 122, 1565-1575.	2.0	35
75	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.	2.5	35
76	Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 521-528.	2.0	34
77	A phase II/III randomized, multicenter trial of prednisone/sirolimus <i>versus</i> prednisone/sirolimus/calcineurin inhibitor for the treatment of chronic graft-<i>versus</i>-host disease: BMT CTN 0801. <i>Haematologica</i> , 2018, 103, 1915-1924.	1.7	34
78	Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study. , 2020, 8, e001302.		34
79	Effect of Progenitor Cell Mobilization With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Peripheral Artery Disease. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 2631.	3.8	33
80	Circadian Variation in Vascular Function and Regenerative Capacity in Healthy Humans. <i>Journal of the American Heart Association</i> , 2014, 3, e000845.	1.6	33
81	Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 202-208.	2.0	33
82	New Cancers after Autotransplantations for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 738-745.	2.0	33
83	Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 540-551.	2.0	32
84	Pharmacokinetic-Directed High-Dose Busulfan Combined with Cyclophosphamide and Etoposide Results in Predictable Drug Levels and Durable Long-Term Survival in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1287-1294.	2.0	31
85	Bone Marrow Mesenchymal Stromal Cells from Patients with Acute and Chronic Graft-versus-Host Disease Deploy Normal Phenotype, Differentiation Plasticity, and Immune-Suppressive Activity. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 934-940.	2.0	31
86	Sex Differences in Circulating Progenitor Cells. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	31
87	A Prospective Trial of Extracorporeal Photopheresis for Chronic Graft-versus-Host Disease Reveals Significant Disease Response and No Association with Frequency of Regulatory T Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2373-2380.	2.0	31
88	Absence of Vasoactive Intestinal Peptide Expression in Hematopoietic Cells Enhances Th1 Polarization and Antiviral Immunity in Mice. <i>Journal of Immunology</i> , 2011, 187, 1057-1065.	0.4	30
89	Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 616-632.	2.0	29
90	Pharmacoeconomic Analysis of Palifermin to Prevent Mucositis among Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 852-857.	2.0	29

#	ARTICLE	IF	CITATIONS
91	KIR Donor Selection: Feasibility in Identifying better Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e28-e32.	2.0	28
92	Chronic GvHD decreases antiviral immune responses in allogeneic BMT. <i>Blood</i> , 2007, 109, 4548-4556.	0.6	27
93	Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. <i>Blood Advances</i> , 2018, 2, 933-940.	2.5	27
94	Recombinant TLR5 Agonist CBLB502 Promotes NK Cell-Mediated Anti-CMV Immunity in Mice. <i>PLoS ONE</i> , 2014, 9, e96165.	1.1	27
95	Allogeneic T Cells Treated with Amotosalen Prevent Lethal Cytomegalovirus Disease without Producing Graft-versus-Host Disease Following Bone Marrow Transplantation. <i>Journal of Immunology</i> , 2003, 171, 6023-6031.	0.4	26
96	Facilitating T-cell immune reconstitution after haploidentical transplantation in adults. <i>Blood Cells, Molecules, and Diseases</i> , 2004, 33, 233-237.	0.6	26
97	Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. <i>Blood Advances</i> , 2019, 3, 875-883.	2.5	25
98	Unique molecular characteristics and microglial origin of Kv1.3 channel-positive brain myeloid cells in Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	25
99	Activation, Immune Polarization, and Graft-versus-Leukemia Activity of Donor T Cells Are Regulated by Specific Subsets of Donor Bone Marrow Antigen-Presenting Cells in Allogeneic Hemopoietic Stem Cell Transplantation. <i>Journal of Immunology</i> , 2009, 183, 7799-7809.	0.4	24
100	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020, 105, 1329-1338.	1.7	23
101	Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing. <i>Cytotherapy</i> , 2022, 24, 869-878.	0.3	23
102	Receiver operating characteristic curve analysis of circulating blood dendritic cell precursors and T cells predicts response to extracorporeal photopheresis in patients with chronic graft-versus-host disease. <i>Transfusion</i> , 2010, 50, 2424-2431.	0.8	22
103	Reconstructing Immunity After Allogeneic Transplantation. <i>Immunologic Research</i> , 2004, 29, 269-282.	1.3	21
104	Modulation of Immune Checkpoints and Graft-versus-Leukemia in Allogeneic Transplants by Antagonizing Vasoactive Intestinal Peptide Signaling. <i>Cancer Research</i> , 2016, 76, 6802-6815.	0.4	21
105	Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 270-278.	2.0	21
106	Modulation of antitumor immune responses by hematopoietic cytokines. <i>Cancer</i> , 2003, 97, 1797-1809.	2.0	20
107	Impact of the posttransplant lymphoproliferative disorder subtype on survival. <i>Cancer</i> , 2018, 124, 2327-2336.	2.0	20
108	Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells. <i>Transfusion</i> , 2007, 47, 629-635.	0.8	19

#	ARTICLE	IF	CITATIONS
109	Temporal Changes in Plerixafor Administration and Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1393-1395.	2.0	18
110	Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 973-982.	2.0	18
111	Circulating Progenitor Cells and Racial Differences. <i>Circulation Research</i> , 2018, 123, 467-476.	2.0	18
112	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.	2.5	18
113	Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantation. <i>Blood Advances</i> , 2022, 6, 746-749.	2.5	18
114	Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2022, 57, 911-917.	1.3	18
115	Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1197-1205.	2.0	17
116	Cardiovascular Risk and Resilience Among Black Adults: Rationale and Design of the MECA Study. <i>Journal of the American Heart Association</i> , 2020, 9, e015247.	1.6	17
117	PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients. <i>PLoS ONE</i> , 2017, 12, e0184254.	1.1	17
118	Posttransplant Thrombopoiesis Predicts Survival in Patients Undergoing Autologous Hematopoietic Progenitor Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 895-904.	2.0	16
119	VIPhyb, an Antagonist of Vasoactive Intestinal Peptide Receptor, Enhances Cellular Antiviral Immunity in Murine Cytomegalovirus Infected Mice. <i>PLoS ONE</i> , 2013, 8, e63381.	1.1	16
120	Differential effects of nebivolol and metoprolol on arterial stiffness, circulating progenitor cells, and oxidative stress. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 206-213.	2.3	16
121	Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K- $\hat{\gamma}$ and $\hat{\mu}$. <i>Frontiers in Immunology</i> , 2021, 12, 718621.	2.2	16
122	Cellular immunotherapy and cancer. <i>Seminars in Oncology</i> , 2004, 31, 87-90.	0.8	15
123	Persistence of Varicella-Zoster Virus-Specific Plasma Cells in Adult Human Bone Marrow following Childhood Vaccination. <i>Journal of Virology</i> , 2020, 94, .	1.5	15
124	Pharmacological inhibition of VIP signaling enhances antiviral immunity and improves survival in murine cytomegalovirus-infected allogeneic bone marrow transplant recipients. <i>Blood</i> , 2013, 121, 2347-2351.	0.6	14
125	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1875-1883.	2.0	14
126	The association of CMV with NK-cell reconstitution depends on graft source: results from BMT CTN-0201 samples. <i>Blood Advances</i> , 2019, 3, 2465-2469.	2.5	14

#	ARTICLE	IF	CITATIONS
127	Association Between Change in Circulating Progenitor Cells During Exercise Stress and Risk of Adverse Cardiovascular Events in Patients With Coronary Artery Disease. <i>JAMA Cardiology</i> , 2020, 5, 147.	3.0	14
128	Indole derivatives, microbiome and graft versus host disease. <i>Current Opinion in Immunology</i> , 2021, 70, 40-47.	2.4	14
129	T-follicular helper cell expansion and chronic T-cell activation are characteristic immune anomalies in Evans syndrome. <i>Blood</i> , 2022, 139, 369-383.	0.6	14
130	Allogeneic HSCT Patients Receiving More RBC Transfusions Are At Increased Risk For Development Of Grade 2-4 Acute Graft-Versus-Host Disease. <i>Blood</i> , 2013, 122, 3298-3298.	0.6	14
131	The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1325-1330.	2.0	13
132	Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors. <i>Haematologica</i> , 2019, 104, 844-854.	1.7	13
133	Host and Donor Immune Responses Contribute to Antiviral Effects of Amotosalen-Treated Donor Lymphocytes following Early Posttransplant Cytomegalovirus Infection. <i>Journal of Immunology</i> , 2008, 180, 6892-6902.	0.4	12
134	Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 552-558.	2.0	12
135	Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2021, 5, 4980-4991.	2.5	12
136	Enrichment of IL-12 α -Producing Plasmacytoid Dendritic Cells in Donor Bone Marrow Grafts Enhances Graft-versus-Leukemia Activity in Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1331-1339.	2.0	11
137	Evaluation of the spectra Optia $\text{\textcircled{R}}$ mononuclear cell collection procedure in multiple myeloma patients. <i>Journal of Clinical Apheresis</i> , 2015, 30, 1-7.	0.7	11
138	Circulating progenitor cells and coronary microvascular dysfunction: Results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation $\text{\textcircled{R}}$ Coronary Vascular Dysfunction Study (WISE-CVD). <i>Atherosclerosis</i> , 2016, 253, 111-117.	0.4	11
139	Circulating Progenitor Cells is Linked to Cognitive Decline in Healthy Adults. <i>American Journal of the Medical Sciences</i> , 2016, 351, 147-152.	0.4	11
140	Flow cytometric data analysis of circulating progenitor cell stability. <i>Data in Brief</i> , 2017, 10, 346-348.	0.5	11
141	Administration of a vasoactive intestinal peptide antagonist enhances the autologous anti-leukemia T cell response in murine models of acute leukemia. <i>OncImmunology</i> , 2017, 6, e1304336.	2.1	11
142	Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 699-711.	2.0	11
143	Myeloablative busulfan/cytosan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 837-843.	0.6	10
144	Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1744-1755.	2.0	10

#	ARTICLE	IF	CITATIONS
145	Flt3L Treatment of Bone Marrow Donors Increases Graft Plasmacytoid Dendritic Cell Content and Improves Allogeneic Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1075-1084.	2.0	10
146	From Single Nucleotide Polymorphisms to Constant Immunosuppression: Mesenchymal Stem Cell Therapy for Autoimmune Diseases. <i>BioMed Research International</i> , 2013, 2013, 1-8.	0.9	9
147	Activation of VIP signaling enhances immunosuppressive effect of MDSCs on CMV-induced adaptive immunity. <i>Oncotarget</i> , 2017, 8, 81873-81879.	0.8	9
148	Amotosalen-treated donor T cells have polyclonal antigen-specific long-term function without graft-versus-host disease after allogeneic bone marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 169-180.	2.0	8
149	Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation—A Similar Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 746-747.	2.0	8
150	Microfluidic Platform to Transduce Cell Viability to Distinct Flow Pathways for High-Accuracy Sensing. <i>ACS Sensors</i> , 2021, 6, 3789-3799.	4.0	8
151	Results of a Multicenter Pilot Investigation of Bone Marrow Transplantation in Adults with Sickle Cell Disease (STRIDE). <i>Blood</i> , 2015, 126, 543-543.	0.6	8
152	Properties of Immature Myeloid Progenitors with Nitric-Oxide-Dependent Immunosuppressive Activity Isolated from Bone Marrow of Tumor-Free Mice. <i>PLoS ONE</i> , 2013, 8, e64837.	1.1	8
153	Graft engineering using ex vivo methods to limit GVHD: Fludarabine treatment generates superior GVL effects in allogeneic BMT. <i>Experimental Hematology</i> , 2006, 34, 895-904.	0.2	7
154	Similar Survival for Patients Undergoing Reduced-Intensity Total Body Irradiation (TBI) Versus Myeloablative TBI as Conditioning for Allogeneic Transplant in Acute Leukemia. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 360-369.	0.4	7
155	Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 383-389.	0.6	7
156	Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report. <i>International Journal of Molecular Sciences</i> , 2018, 19, 4118.	1.8	7
157	Myocardial Ischemia and Mobilization of Circulating Progenitor Cells. <i>Journal of the American Heart Association</i> , 2018, 7, e007504.	1.6	7
158	Stiffness based enrichment of leukemia cells using microfluidics. <i>APL Bioengineering</i> , 2020, 4, 036101.	3.3	7
159	Vascular Regenerative Capacity and the Obesity Paradox in Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2097-2108.	1.1	7
160	Natural suppressor cells past present and future. <i>Frontiers in Bioscience - Elite</i> , 2012, E4, 1237-1245.	0.9	7
161	Donor plasmacytoid dendritic cells limit graft-versus-host disease through vasoactive intestinal polypeptide expression. <i>Blood</i> , 2022, 140, 1431-1447.	0.6	7
162	Natural suppressor cells; past, present and future. <i>Frontiers in Bioscience - Elite</i> , 2012, E4, 1237.	0.9	6

#	ARTICLE	IF	CITATIONS
163	Host bone marrow-derived IL-12 enhances donor T cell engraftment in a mouse model of bone marrow transplantation. <i>Journal of Hematology and Oncology</i> , 2014, 7, 16.	6.9	6
164	Plerixafor in combination with granulocyte colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial. <i>Transfusion</i> , 2015, 55, 2351-2357.	0.8	6
165	Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. <i>British Journal of Cancer</i> , 2020, 123, 1228-1234.	2.9	6
166	Circulating Progenitor Cells and Cognitive Impairment in Men and Women with Coronary Artery Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 659-668.	1.2	6
167	Irradiated Donor Leukocytes Promote Engraftment of Allogeneic Bone Marrow in Major Histocompatibility Complex Mismatched Recipients Without Causing Graft-Versus-Host Disease. <i>Blood</i> , 1999, 94, 3222-3233.	0.6	6
168	Changes in the pattern of TCR V β 2 repertoire expression after bone marrow transplant is linked to the HLA haplotype in humans. <i>British Journal of Haematology</i> , 2001, 113, 224-230.	1.2	5
169	Chemokine and lymph node homing receptor expression on pDC vary by graft source. <i>Oncolmmunology</i> , 2014, 3, e958957.	2.1	5
170	Recipient single nucleotide polymorphisms in Paneth cell antimicrobial peptide genes and acute graft-versus-host disease: analysis of BMT CTN0201 and 0901 samples. <i>British Journal of Haematology</i> , 2018, 182, 887-894.	1.2	5
171	The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. , 2020, 8, e000810.		5
172	Circulating Progenitor Cells in Patients With Coronary Artery Disease and Renal Insufficiency. <i>JACC Basic To Translational Science</i> , 2020, 5, 770-782.	1.9	5
173	A new role for an old cytokine: GM-CSF amplifies GVHD. <i>Blood</i> , 2020, 135, 520-521.	0.6	5
174	Development of iron deficiency anemia in patients undergoing extracorporeal photopheresis: Comparison of the UVAR and CELLEX instruments. <i>Journal of Clinical Apheresis</i> , 2021, 36, 34-40.	0.7	5
175	Temporal Changes in Plerixafor Administration Do Not Impact Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial. <i>Blood</i> , 2011, 118, 2988-2988.	0.6	5
176	Treatment of severe neutropenia with high-dose pyridoxine in a patient with chronic graft versus host disease and squamous cell carcinoma: a case report. <i>Journal of Medical Case Reports</i> , 2011, 5, 372.	0.4	4
177	A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma. <i>Transfusion</i> , 2013, 53, 76-84.	0.8	4
178	Evaluation of peripheral blood stem cell quality in products transported by traditional courier or commercial overnight shipping services. <i>Transfusion</i> , 2014, 54, 1501-1507.	0.8	4
179	A GMCSF and IL7 fusion cytokine leads to functional thymic-dependent T-cell regeneration in age-associated immune deficiency. <i>Clinical and Translational Immunology</i> , 2015, 4, e37.	1.7	4
180	Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 514-518.	0.2	4

#	ARTICLE	IF	CITATIONS
181	GM-CSF and IL-4 Fusion Cytokine Induces B Cell-Dependent Hematopoietic Regeneration. <i>Molecular Therapy</i> , 2017, 25, 416-426.	3.7	4
182	Safety and survival outcomes for bloodless transplantation in patients with myeloma. <i>Cancer</i> , 2019, 125, 185-193.	2.0	4
183	Genetics of HLA Peptide Presentation and Impact on Outcomes in HLA-Matched Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 591-599.	0.6	4
184	Evaluation of In Vivo CAR Transgene Levels in Relapsed/Refractory Pediatric and Young Adult ALL and Adult DLBCL Tisagenlecleucel-Treated Patients. <i>Blood</i> , 2018, 132, 899-899.	0.6	4
185	A randomized clinical trial comparing granulocyte colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation. <i>Transfusion</i> , 2011, 51, 1779-1783.	0.8	3
186	New molecule for mobilizing marrow stem cells. <i>Blood</i> , 2014, 123, 310-311.	0.6	3
187	Referral Patterns and Clinical Outcomes for Transplant-Eligible Lymphoma and Myeloma Patients Evaluated at an Urban County Hospital. <i>Journal of Stem Cell Research & Therapy</i> , 2016, 06, .	0.3	3
188	Improving cancer-specific outcomes in solid organ transplant recipients: Where to begin?. <i>Cancer</i> , 2019, 125, 838-842.	2.0	3
189	Associations Between Inflammation, Cardiovascular Regenerative Capacity, and Cardiovascular Events: A Cohort Study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2814-2822.	1.1	3
190	Immunogenicity of tisagenlecleucel in relapsed/ refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3044-3044.	0.8	3
191	Incidence and Geographic Distribution of Adult Acute Leukemia in the State of Georgia. <i>Southern Medical Journal</i> , 2014, 107, 497-500.	0.3	3
192	Preliminary Safety and Efficacy Data Using CDX-301 (Flt3 ligand) As a Sole Agent to Mobilize Hematopoietic Cells Prior to HLA-Matched Sibling Donor Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S324-S325.	2.0	2
193	Mobilizing plasmacytoid dendritic cells. <i>Blood</i> , 2017, 129, 2600-2602.	0.6	2
194	Rationale and design of the granulocyte-macrophage colony stimulating factor in peripheral arterial disease (GPAD-3) study. <i>Contemporary Clinical Trials</i> , 2020, 91, 105975.	0.8	2
195	T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes. <i>Blood</i> , 2018, 132, 1015-1015.	0.6	2
196	Safety and Efficacy of Evomela, in Myeloma Autotransplants. <i>Blood</i> , 2018, 132, 3446-3446.	0.6	2
197	A Phase I Trial of Ara-C, Topotecan, and Gemtuzumab Ozogamicin (Mylotarg®) for Advanced MDS and Secondary or Relapsed AML.. <i>Blood</i> , 2004, 104, 1814-1814.	0.6	2
198	A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration.. <i>Blood</i> , 2008, 112, 3332-3332.	0.6	2

#	ARTICLE	IF	CITATIONS
199	Circulating progenitor cells are reduced in HIV-positive, anti-retroviral naïve patients. <i>International Journal of Cardiology</i> , 2014, 176, 1150-1152.	0.8	1
200	Association between recipient TNF rs361525 and acute GVHD: results from analysis of BMT CTN-0201 samples. <i>Bone Marrow Transplantation</i> , 2018, 53, 1069-1071.	1.3	1
201	Analysis of BMT CTN-0201 and -0901 samples did not reproduce the reported association between recipient REG3A rs7588571 and chronic GVHD. <i>Bone Marrow Transplantation</i> , 2019, 54, 490-493.	1.3	1
202	Answer to May 2021 Photo Quiz. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	1.8	1
203	Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 2157-2157.	0.6	1
204	Impact of In Vivo T-Cell Depletion on Outcome of Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies impact of In Vivo T-Cell Depletion on Outcome of Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies. <i>Blood</i> , 2010, 116, 2305-2305.	0.6	1
205	The Absence of Vasoactive Intestinal Peptide Augments Allo-Reactivity and the Anti-Viral Response in Bone Marrow Transplantation.. <i>Blood</i> , 2007, 110, 3267-3267.	0.6	1
206	Donor Dendritic Cells Home to Lymphoid Organs in Allogeneic Transplant Recipients, Enhance Donor T-Cell Chimerism, and Polarize Donor T-Cell Activation.. <i>Blood</i> , 2009, 114, 62-62.	0.6	1
207	A First-in-Disease Trial of in Vivo Costimulation Blockade for Acute GvHD Prevention: The Addition of Abatacept to Standard GvHD Prophylaxis Controls Early CD4+ T Cell Proliferation and Is Associated with Low Rates of Severe Acute GvHD. <i>Blood</i> , 2012, 120, 741-741.	0.6	1
208	Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma. <i>Blood Advances</i> , 0, , .	2.5	1
209	The cross-disciplinary intellectual stream of <i>ImmunoMedicine</i> . <i>Immunomedicine</i> , 2021, 1, e1009.	0.7	0
210	Photo Quiz: Strength in Numbers—a Disseminated Infection Causing Shortness of Breath. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	1.8	0
211	MCMV Infection Lowers the Threshold for the Development of Clinical GvHD after Allogeneic Bone Marrow Transplantation.. <i>Blood</i> , 2004, 104, 2125-2125.	0.6	0
212	Predictors of More Rapid Lymphoid Reconstitution after Allogeneic Transplantation.. <i>Blood</i> , 2004, 104, 3159-3159.	0.6	0
213	Relapse Free Survival of Elderly AML Patients Is Comparable to That of Younger Adults When Treated with a Modified Dose Intensive Cytarabine Regimen.. <i>Blood</i> , 2005, 106, 4634-4634.	0.6	0
214	Decreased Incidence of Relapse in Patients with Acute Leukemia Transplanted from Matched Unrelated Donors: Induction of GvL.. <i>Blood</i> , 2005, 106, 2016-2016.	0.6	0
215	Prophylactic Amotosalen-Treated Donor T-Cells Prevent Late CMV Infection in Allogeneic Bone Marrow Transplantation.. <i>Blood</i> , 2005, 106, 3024-3024.	0.6	0
216	Allogeneic Transplantation for Multiple Myeloma. , 2008, , 125-142.		0

#	ARTICLE	IF	CITATIONS
217	Patulin Acts Synergistically with Doxorubicin and Bortezomib in Cytotoxicity against Hematological Malignancies. <i>Blood</i> , 2008, 112, 2664-2664.	0.6	0
218	Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] Is An Effective Induction Regimen for Advanced MDS and Secondary or Relapsed AML: Analysis of a Phase I/II Study. <i>Blood</i> , 2008, 112, 3644-3644.	0.6	0
219	Higher Numbers of Circulating Dendritic Cells and T-Cells Predict Response to Extracorporeal Photopheresis in Patients with Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2008, 112, 1183-1183.	0.6	0
220	Flagellin, a TLR5 Agonist, Down-Regulate CD62L on Donor T Cells and Limit GvHD in Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2008, 112, 3521-3521.	0.6	0
221	Anti-Viral Immunity to CMV Reactivation in Allogeneic HSCT Recipients.. <i>Blood</i> , 2009, 114, 1165-1165.	0.6	0
222	A Randomized Clinical Trial Comparing Cytokine Administration Sites for Mobilization of Peripheral Hematopoietic Progenitor Cells for Patients with Hematological Malignancies Undergoing Autologous Stem Cell Transplantation.. <i>Blood</i> , 2009, 114, 4230-4230.	0.6	0
223	Prophylactic Use of Flagellin: A Novel Method to Boost Immune Reconstitution in Allogeneic HSCT Recipients with Limited GvHD.. <i>Blood</i> , 2009, 114, 3561-3561.	0.6	0
224	Targeting PKCtheta Inhibits Alloreactivity and Graft-Versus-Host Disease While Preserving Graft-Versus-Leukemia and Anti-Infection Activities.. <i>Blood</i> , 2009, 114, 2458-2458.	0.6	0
225	Thrombocytopenia Induced by Combination Administration of Romidepsin and Bortezomib In Mice Is Rapidly Reversible After Drug Treatment. <i>Blood</i> , 2010, 116, 4909-4909.	0.6	0
226	Flagellin, a TLR5 Agonist, Reduces GvHD in Allogeneic HSCT Recipients While Enhancing Anti-Viral Immunity: A Novel Therapeutic Approach. <i>Blood</i> , 2011, 118, 144-144.	0.6	0
227	Equivalent Survival Following Fludarabine/Melphalan Reduced Intensity Conditioning with or without Rabbit ATG As Part of GvHD Prophylaxis. <i>Blood</i> , 2011, 118, 1959-1959.	0.6	0
228	Reduced Intensity or Non-Ablative Hematopoietic Cell Transplantation in Older Patients with Non-Hodgkin Lymphoma (NHL): Encouraging Survival for Patients ≥55 Years. <i>Blood</i> , 2011, 118, 1015-1015.	0.6	0
229	Advanced Non Small Cell Lung Cancer Patients with Fewer Numbers of Blood Myeloid Dendritic Cells and CD4 Cells Prior to Treatment Have Inferior Progression-Free Survival: Implications for Cancer Immunotherapy. <i>Blood</i> , 2012, 120, 4837-4837.	0.6	0
230	Incidence and Geographic Distribution of Adult Acute Lymphoblastic Leukemia in the State of Georgia. <i>Blood</i> , 2012, 120, 4309-4309.	0.6	0
231	Efficacy Of a Pharmacokinetics-Directed IV Busulfan (Bu), Plus Cyclophosphamide (Cy) and Etoposide (E) Preparative Regimen With Autologous Hematopoietic Stem Cell Transplantation For Lymphoma: Final Report Of a Multi-Center Phase 2 Study In North America. <i>Blood</i> , 2013, 122, 768-768.	0.6	0
232	Expression Of PD-L1 Is Required To Control Acute GvHD In Allo-HSCT Recipients. <i>Blood</i> , 2013, 122, 2008-2008.	0.6	0
233	VIP-Receptor Antagonist Enhanced Antileukemic Activity In Mice. <i>Blood</i> , 2013, 122, 1664-1664.	0.6	0
234	Vasoactive Intestinal Peptide Synthesis in Transplant Recipients Critically Regulate Donor T Cell Alloreactivity and Graft-Versus-Host Disease. <i>Blood</i> , 2018, 132, 480-480.	0.6	0

#	ARTICLE	IF	CITATIONS
235	Ixazomib with or without Rituximab Following Immunochemotherapy and Autologous Stem Cell Transplant in Mantle Cell Lymphoma. <i>Blood</i> , 2020, 136, 39-39.	0.6	0
236	Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era. <i>Blood</i> , 2020, 136, 20-21.	0.6	0
237	Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens. <i>Blood</i> , 2020, 136, 21-22.	0.6	0
238	Comparing VIP and PD-1 expression as cancer biomarkers. <i>Immunomedicine</i> , 0, , .	0.7	0